Loading
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Latest quote
$1.87
+$0.07 · +3.89%
After-hours
$1.87
$0.00 · 0.00%
Sep 14, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Day range
Current $1.87
52-week range
Current $1.87
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
40
Expensive
Sentiment
56
Mixed
Risk
60
Elevated Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Day range
Current $1.87
52-week range
Current $1.87
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 94.48M USD | 38.32M USD | 16.46M USD | 15.47M USD | 12.46M USD |
| Selling, general, and administrative | 28.69M USD | 23.98M USD | 8.47M USD | 3.26M USD | 3.16M USD |
| Operating expenses | 123.17M USD | 62.3M USD | 26.06M USD | 19.43M USD | 15.87M USD |
| Interest income | 9.43M USD | 10.41M USD | 1.12M USD | 129K USD | 25K USD |
| Interest expense | 2.99M USD | 2.8M USD | 4.95M USD | 1.42M USD | 5.02M USD |
| Depreciation and amortization | 509K USD | 323K USD | 175K USD | 238K USD | 272K USD |
| Operating income | −123.17M USD | −62.3M USD | −26.06M USD | −19.43M USD | −15.87M USD |
| Net income | −117.3M USD | −55.14M USD | −99.92M USD | −24.46M USD | −23.44M USD |
Company facts updated Sep 15, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
